- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…Endpoints · 2mo ago↗ source
- Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 2mo ago↗ source
- Renal Cell Carcinoma: Real-World Factors in First-Line Treatment SelectionIn this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.